Pulse Biosciences (NASDAQ:PLSE – Get Free Report) is set to announce its earnings results after the market closes on Wednesday, October 30th. Parties that wish to register for the company’s conference call can do so using this link.
Pulse Biosciences Stock Performance
PLSE opened at $17.62 on Monday. The stock has a market capitalization of $1.08 billion, a P/E ratio of -21.75 and a beta of 1.74. Pulse Biosciences has a one year low of $3.78 and a one year high of $22.69. The business’s 50-day simple moving average is $17.88 and its 200-day simple moving average is $14.05.
Wall Street Analyst Weigh In
Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Friday, September 20th.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
- Five stocks we like better than Pulse Biosciences
- About the Markup Calculator
- GM’s Lithium Americas Deal Positions It for EV Dominance
- High Flyers: 3 Natural Gas Stocks for March 2022
- Amazon: Why Analysts Think It’s A Solid Buy Ahead Of Earnings
- How to Choose Top Rated Stocks
- NextEra’s Diverse Business Is Set to Win As Energy Demand Rises
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
